OverviewSuggest Edit

Jazz Pharmaceuticals is an international biopharmaceutical company, focused on identifying, developing and commercializing products for neurology and psychiatry. The Company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning.

TypePublic
Founded2003
HQDublin 4, IE
Websitejazzpharma.com
Employee Ratings4

Latest Updates

Employees (est.) (Jul 2021)1,940
Job Openings95
Revenue (FY, 2020)$2.4 B(+10%)
Share Price (Sept 2021)$134.9
Cybersecurity ratingBMore

Key People/Management at Jazz Pharmaceuticals

Finbar Larkin

Finbar Larkin

Senior Vice President, Technical Operations
Bruce C. Cozadd

Bruce C. Cozadd

Chairman and Chief Executive Officer
Heidi Manna

Heidi Manna

Senior Vice President and Chief Human Resources Officer
Paul L. Berns

Paul L. Berns

Director
Renée Galá

Renée Galá

Executive Vice President and Chief Financial Officer
Patrick G. Enright

Patrick G. Enright

Director
Show more

Jazz Pharmaceuticals Office Locations

Jazz Pharmaceuticals has offices in Dublin 4, Athlone, Palo Alto, Philadelphia and in 7 other locations
Dublin 4, IE (HQ)
Waterloo Rd, Ballsbridge
Athlone, IE
Sli An Aifrinn, Warrens Fields
Mississauga, CA
602-4080 Confederation Pkwy
Vancouver, CA
887 Great Northern Way
Lyon, FR
84 Quai Charles de Gaulle
München, DE
Grillparzerstraße 18
Show all (11)

Jazz Pharmaceuticals Financials and Metrics

Jazz Pharmaceuticals Revenue

Jazz Pharmaceuticals's revenue was reported to be $2.36 b in FY, 2020
USD

Revenue (Q1, 2021)

607.6m

Net income (Q1, 2021)

121.8m

EBIT (Q1, 2021)

162.1m

Market capitalization (14-Sept-2021)

8.3b

Closing stock price (14-Sept-2021)

134.9

Cash (31-Mar-2021)

2.1b

EV

8.3b
Jazz Pharmaceuticals's current market capitalization is $8.3 b.
USDQ2, 2011

Financial Leverage

1.9 x
Show all financial metrics

Jazz Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
CavionAugust 13, 2019$312.5 m

Jazz Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Jazz Pharmaceuticals Online and Social Media Presence

Embed Graph

Jazz Pharmaceuticals News and Updates

Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution

U.S. Food and Drug Administration published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy by means of greater safety compared to Xyrem® (sodium oxybate) Xywav...

Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc

DUBLIN, June 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today updated its full year 2021 financial guidance to incorporate the GW Pharmaceuticals (GW) business, which the Company acquired on May 5, 2021. "We expect 2021 to be another exciting, productive and...

Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Community

DUBLIN, June 14, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Nothing Small About It (www.nothingsmallaboutit.com), an online program developed with consultation from leading cancer organizations CancerCare, GO2 Foundation for Lung Cancer,...

Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021

DUBLIN, June 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35th annual meeting of the Associated Professional...

Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes

DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company") announced today that its wholly owned subsidiary, Jazz Securities Designated Activity Company (the "Issuer"), is commencing a private offering (the "Offering") of senior secured notes (the...

Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting

DUBLIN, April 20, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented...
Show more

Jazz Pharmaceuticals Blogs

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021 Content Import Mon, 09/13/2021 - 16:16 Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, …

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences

Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences Content Import Wed, 09/08/2021 - 16:16 Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences September 08, 2021 This release is a backfill from a News Wire…

Jazz Pharmaceuticals Announces Health Canada Approval of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals Announces Health Canada Approval of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea Content Import Tue, 08/31/2021 - 08:04 Jazz Pharmaceuticals Announces Health Canada Approval of Sunosi® (solriamfetol) for …

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults Content Import Thu, 08/12/2021 - 14:30 Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassiu…

Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results

Closed GW Pharmaceuticals plc Acquisition, Creating an Innovative, High-Growth, Global Biopharma Leader 41% of Net Product Sales from Recently Launched or Acquired Products Strong Xywav™ Adoption with 5,100 Active Patients Exiting the Second Quarter FDA Approval and Launch of Rylaze™ in the U.S.

National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia

National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia Content Import Thu, 07/22/2021 - 16:16 National Comprehensive Cancer Network® Adds Newly Ap…
Show more

Jazz Pharmaceuticals Frequently Asked Questions

  • When was Jazz Pharmaceuticals founded?

    Jazz Pharmaceuticals was founded in 2003.

  • Who are Jazz Pharmaceuticals key executives?

    Jazz Pharmaceuticals's key executives are Finbar Larkin, Bruce C. Cozadd and Heidi Manna.

  • How many employees does Jazz Pharmaceuticals have?

    Jazz Pharmaceuticals has 1,940 employees.

  • What is Jazz Pharmaceuticals revenue?

    Latest Jazz Pharmaceuticals annual revenue is $2.4 b.

  • What is Jazz Pharmaceuticals revenue per employee?

    Latest Jazz Pharmaceuticals revenue per employee is $1.2 m.

  • Who are Jazz Pharmaceuticals competitors?

    Competitors of Jazz Pharmaceuticals include UCB, Teva and Takeda.

  • Where is Jazz Pharmaceuticals headquarters?

    Jazz Pharmaceuticals headquarters is located at Waterloo Rd, Ballsbridge, Dublin 4.

  • Where are Jazz Pharmaceuticals offices?

    Jazz Pharmaceuticals has offices in Dublin 4, Athlone, Palo Alto, Philadelphia and in 7 other locations.

  • How many offices does Jazz Pharmaceuticals have?

    Jazz Pharmaceuticals has 11 offices.